X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PIRAMAL ENTERPRISES NATCO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 19.8 8.9 223.1% View Chart
P/BV x 19.0 2.9 644.6% View Chart
Dividend Yield % 0.6 0.8 72.9%  

Financials

 NATCO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-17
NATCO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8772,095 41.9%   
Low Rs4241,025 41.3%   
Sales per share (Unadj.) Rs223.4492.8 45.3%  
Earnings per share (Unadj.) Rs31.172.6 42.8%  
Cash flow per share (Unadj.) Rs40.394.7 42.5%  
Dividends per share (Unadj.) Rs5.0021.00 23.8%  
Dividend yield (eoy) %0.81.3 57.1%  
Book value per share (Unadj.) Rs219.5862.5 25.5%  
Shares outstanding (eoy) m33.07172.56 19.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.2 91.9%   
Avg P/E ratio x20.921.5 97.3%  
P/CF ratio (eoy) x16.116.5 98.0%  
Price / Book Value ratio x3.01.8 163.8%  
Dividend payout %16.128.9 55.6%   
Avg Mkt Cap Rs m21,504269,194 8.0%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m1,12817,939 6.3%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m7,38985,037 8.7%  
Other income Rs m1672,338 7.1%   
Total revenues Rs m7,55687,374 8.6%   
Gross profit Rs m1,79334,991 5.1%  
Depreciation Rs m3043,817 8.0%   
Interest Rs m36620,310 1.8%   
Profit before tax Rs m1,29013,202 9.8%   
Minority Interest Rs m461,699 2.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m3092,281 13.5%   
Profit after tax Rs m1,02712,520 8.2%  
Gross profit margin %24.341.1 59.0%  
Effective tax rate %23.917.3 138.5%   
Net profit margin %13.914.7 94.4%  
BALANCE SHEET DATA
Current assets Rs m3,68187,590 4.2%   
Current liabilities Rs m3,123185,578 1.7%   
Net working cap to sales %7.6-115.2 -6.6%  
Current ratio x1.20.5 249.8%  
Inventory Days Days8931 288.3%  
Debtors Days Days5948 123.4%  
Net fixed assets Rs m7,685108,523 7.1%   
Share capital Rs m331345 95.8%   
"Free" reserves Rs m6,670148,481 4.5%   
Net worth Rs m7,259148,826 4.9%   
Long term debt Rs m955144,957 0.7%   
Total assets Rs m11,957482,394 2.5%  
Interest coverage x4.51.7 274.1%   
Debt to equity ratio x0.11.0 13.5%  
Sales to assets ratio x0.60.2 350.6%   
Return on assets %11.76.8 171.3%  
Return on equity %14.28.4 168.2%  
Return on capital %20.712.0 173.4%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44515,001 23.0%   
Fx outflow Rs m7035,150 13.6%   
Net fx Rs m2,7439,851 27.8%   
CASH FLOW
From Operations Rs m1,440-100,393 -1.4%  
From Investments Rs m-1,089-24,202 4.5%  
From Financial Activity Rs m-353135,705 -0.3%  
Net Cashflow Rs m-111,110 -0.0%  

Share Holding

Indian Promoters % 52.0 52.9 98.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.0 196.0%  
FIIs % 16.6 26.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 16.5 157.6%  
Shareholders   25,395 93,274 27.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  ALKEM LABORATORIES  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS